Company: IOBT
Filing Date: 2025-07-24
Form Type: S-3
Source: 0001193125-25-164495
Chunk: 9

Company: IO Biotech, Inc.
Filing Date: 2025-07-24
Form: S-3
Chunk 9
---
. We conduct substantially all
of our operations through our subsidiaries. Our subsidiary, IO Biotech ApS, a corporation domiciled in Denmark, was originally incorporated in December 2014, and holds our intellectual property assets. Our executive offices are located at Ole
Maaløes Vej 3, DK-2200 Copenhagen N, Denmark, and our telephone number is +45 7070 2980. Our website address is iobiotech.com, on which we make available, free of charge, our annual report on 10-K, quarterly reports on 10-Q, and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) as soon as reasonably practicable after we
electronically file or furnish such materials with the SEC. Information contained on, or that can be accessed through, our website is not incorporated by reference into this Annual Report on Form 10-K, and you
should not consider information on our website to be part of this Annual Report on Form 10-K. The SEC also maintains a website that contains reports, proxy and information statements, and other information
regarding issuers that file electronically with the SEC, which can be accessed at www.sec.gov.

4

THE OFFERING

| Common stock offered by the selling stockholders | Up to 4,221,867 shares of our common stock issuable upon the exercise of Warrants held by the selling stockholders. |

| Common stock currently outstanding | 65,880,914 (as of July 1, 2025) |

| The Warrants | The Warrants are immediately exercisable upon issuance at an exercise price of $1.3159 per share, subject to adjustments as set forth therein. The Warrants terminate on the earlier of (i) the date that is twenty years following the issuance 
 and (ii) one day prior to the closing of an Acquisition (as defined in the Warrants).                                                                                                                                                            |

| Selling stockholders | All of the shares of our common stock are being offered by the selling stockholders. See “Selling Stockholders” on beginning on page 11 for additional information on the selling stockholders. |

| Use of Proceeds | We will not receive any proceeds from the sale of the shares in this offering by the selling stockholders, although we may receive proceeds from the cash exercise of any Warrants. See “Use of Proceeds” beginning on page 10 for 
 additional information on the use of proceeds.                                                                                                                                                                                     |

| Registration